C.S. Group, Taiwan’s largest specialized Taiwanofungus Camphoratus retail chain, hosted the ‘Antcin A Veterinary Drug Phase I Trials & 2026 Capital Market Progress Report’ on December 6, 2025. During the briefing, the Group announced that Phase I Pharmacokinetics (PK) trials…
Professional Collaboration and Quality Assurance: Partnering with veterinary networks to provide science-based wellness recommendations. We have established rigorous quality control standards and maintain continuous investment in R&D to explore the therapeutic value of natural ingredients. Our mission is to promote…
C.S. Group is redefining the Taiwanofungus Camphoratus landscape by transitioning the species from a traditional supplement to a novel veterinary pharmaceutical, integrated with an innovative brick-and-mortar retail chain model. This evolution represents more than mere product innovation; it marks…
Dalan Huang, President of C.S. Group, emphasized that superior raw materials are the prerequisite for high-quality finished products. This is why we must first prioritize the optimization of elite strains and the scaling of our cultivation processes. By building a…
The efficacy of Antcin A has long been recognized within the industry. However, the extraction process requires a massive volume of raw material, leading to prohibitive costs that few competitors can overcome. Consequently, market demand significantly outstrips supply. For the…
C.S. Group, a pioneering enterprise listed in the U.S. capital market that specializes in restoring the rare fungal species endemic to Taiwan—Taiwanofungus Camphoratus—through its proprietary innovation in cultivation technology, has recently achieved a successful uplisting to the OTCQB Venture Market.…